Dll3-flox Mouse

Dll3, short for Delta-like ligand 3, is an inhibitory Notch ligand. The Notch signaling pathway is crucial in cell fate determination, development, and tissue homeostasis, and Dll3's role as an inhibitory ligand within this pathway is significant in regulating these processes [1,2,5,6].

Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options. Dll3 is highly expressed in SCLC and other neuroendocrine tumors, but minimally in normal tissues [1,2,5]. Targeted therapies against Dll3 are being developed. For example, the antibody-drug conjugate rovalpituzumab tesirine, the bispecific T cell engager tarlatamab (AMG 757), and the chimeric antigen receptor T cell therapy AMG 119. Tarlatamab has shown manageable safety and encouraging response durability in patients with relapsed/refractory SCLC [1,3,5,6]. Also, IL-18-secreting CAR T cells targeting Dll3 display antitumor efficacy in SCLC models [4].

In conclusion, Dll3's role as an inhibitory Notch ligand is vital in biological regulation. Its overexpression in SCLC and other neuroendocrine tumors makes it a promising therapeutic target. The development of Dll3-targeted therapies offers new hope for treating these aggressive cancers, and further research on Dll3-related mechanisms may lead to more effective treatment strategies [1-4,7,9].